AU4128089A — Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
Assigned to Rorer International Overseas Inc · Expires 1990-03-22 · 36y expired
What this patent protects
The invention relates to therapeutic compositions containing monoclonal antibodies specific to the human epidermal growth factor receptor which are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors in combination with anti-ne…
USPTO Abstract
The invention relates to therapeutic compositions containing monoclonal antibodies specific to the human epidermal growth factor receptor which are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors in combination with anti-neoplastic agents.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.